Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received a consensus rating of “Buy” from the eight brokerages that are currently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.00.

Several equities analysts recently issued reports on the company. Stifel Nicolaus started coverage on Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, September 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Friday, August 16th.

Institutional Trading of Pyxis Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Fullcircle Wealth LLC purchased a new position in shares of Pyxis Oncology in the 2nd quarter valued at about $40,000. SG Americas Securities LLC acquired a new position in Pyxis Oncology in the third quarter valued at approximately $58,000. The Manufacturers Life Insurance Company purchased a new position in Pyxis Oncology in the second quarter valued at approximately $65,000. Cetera Advisors LLC acquired a new stake in Pyxis Oncology during the first quarter worth approximately $100,000. Finally, Schulhoff & Co. Inc. lifted its position in shares of Pyxis Oncology by 90.9% during the 2nd quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after buying an additional 20,000 shares during the last quarter. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock opened at $3.61 on Thursday. The stock has a market capitalization of $212.59 million, a P/E ratio of -2.65 and a beta of 1.27. The business has a 50 day simple moving average of $3.55 and a two-hundred day simple moving average of $3.74. Pyxis Oncology has a 12 month low of $1.35 and a 12 month high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. As a group, research analysts anticipate that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.